# Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

> **NCT00686218** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** panobinostat
- **GENETIC:** polymerase chain reaction
- **GENETIC:** protein expression analysis
- **GENETIC:** western blotting
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00686218
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2013-03
- **Final completion:** 2014-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686218, "Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00686218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*